Updated Data Matrix Available

Market Value | Market Volume | Epidemiology | Clinical Trials | Patent Landscape | Regulatory Approvals

Aneurysmal Subarachnoid Hemorrhage Drugs Market by Drug Class (Opioid Analgesic, Calcium Channel Blocker, Anticonvulsant, Stool Softener, Osmotic Agent/Diuretic, and Other Drugs) and Forecast 2024-2031

$3,000.00

Report Specifications: Market Size, Market Share, Growth Trends, Forecast, Geography

Aneurysmal subarachnoid hemorrhage (aSAH) is a worldwide health burden with high fatality and permanent disability rates. Subarachnoid hemorrhage (SAH) accounts for only around 5% of all strokes but is a major cause of death and disability. Eighty-five per cent of SAH occurs because of rupture of an intra-cranial aneurysm. The estimated worldwide incidence of SAH is 9/100,000 persons per year with regional variation, and 60% of all acute subarachnoid hemorrhages arise in persons aged 40 to 60. The incidence of new cases of SAH in the United States is about 30,000/year or 10/100,000 persons/year. The important risk factors for the development of cerebral aneurysms are hypertension, smoking, chronic alcohol use, family history of intracranial aneurysms in first-degree relatives and female sex.

The overall prognosis depends on the volume of the initial bleed, re-bleeding, and degree of delayed cerebral ischemia (DCI). Cardiac manifestations and neurogenic pulmonary edema indicate the severity of SAH. Acute management focuses on maintenance of adequate ventilation, hemodynamic stabilization, minimizing the risks of re-bleeding, and achieving a rapid diagnosis.

Subsequent treatment aimed at securing the bleeding source and preventing delayed neurological deficits and non-neurological complications. Nimodipine and other calcium channel antagonists substantially decreases the risk of cerebral infarction and poor outcome after aneurysmal SAH. Triple H therapy is the use of hypertension, hypervolaemia, and haemodilution to improve cerebral blood flow (CBF) and oxygen delivery in the treatment of DCI and vasospasm. Magnesium is neuroprotective and having vasodilatatory properties, both of which could be of benefit in SAH. Statins are HMG-CoA (3-hydroxy-3-methyl-glutaryl-CoA reductase) reductase inhibitors used in the management of hypercholesterolaemia. Aggressive endovascular treatment may improve neurological outcome without the risks associated with other treatments such as triple H therapy.

The global aneurysmal subarachnoid hemorrhage drugs market segmentation based on drug class (opioid analgesic, calcium channel blocker, anticonvulsant, stool softener, osmotic agent/diuretic, and other drugs).

The global aneurysmal subarachnoid hemorrhage drugs market research report provides market size ($Million 2021 to 2031), market share analysis, growth trends and forecast (CAGR%, 2024 to 2031). The global aneurysmal subarachnoid hemorrhage drugs market research report is further segmented by geography into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World. In addition, the global aneurysmal subarachnoid hemorrhage drugs market report provides the detailed market landscape (market drivers, restraints, and opportunities), market attractiveness analysis, and market profitability analysis by key products and regions or countries.  The report also tracks the major competitors operating in the global market by company overview, financial snapshot, major products, technologies, services offered and recent developments.

Major players operating in the global aneurysmal subarachnoid hemorrhage drugs market and profiled in this report include Arbor Pharmaceuticals Inc., Edge Therapeutics, Inc., Johnson & Johnson (Actelion Pharmaceuticals Ltd.), Mylan N.V., Orexo AB, Pfizer Inc., Purdue Pharma L.P., Pharmaxis, Ltd., Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd. (Cephalon, Inc.).

DATA INCLUDED: Aneurysmal Subarachnoid Hemorrhage Drugs Market Size, Aneurysmal Subarachnoid Hemorrhage Drugs Market Share, Aneurysmal Subarachnoid Hemorrhage Drugs Market Growth Rates, Aneurysmal Subarachnoid Hemorrhage Drugs Market Trends, and Aneurysmal Subarachnoid Hemorrhage Drugs Market Forecast to 2031

Market Data:

  • Base year for estimation: 2023
  • Actual estimates/Historical data: 2021-2031
  • Forecast period: 2024-2031
  • Market representation: Revenue in $million and CAGR % from 2024 to 2031
  • Regional scope: North America, Europe, Asia Pacific, Latin America, Rest of the World (Middle East & Africa)
  • Country scope: U.S., Canada, U.K., Germany, France, Italy, Spain, Japan, China, India, South Korea, Brazil, Mexico, South Africa, South Korea, Saudi Arabia, UAE and others.
  • Report coverage: Revenue forecast, company share, competitive landscape, growth factors, and trends
  • 15% free customization scope: Any specific or custom requirements, which is not currently within the scope of the report, will be provided as a part of customization.

Qualitative Analysis:

  • Industry overview
  • Industry trends
  • Market drivers and restraints
  • Key market opportunities
  • Market size
  • Growth trends
  • Porter’s five forces analysis
  • Market attractiveness analysis
  • Competitive landscape
    • Company overview
    • Financial performance
    • Product portfolio
    • Strategic insights
    • Recent developments

Quantitative Analysis:

  • Market size estimates and forecast for all segments
  • Regional market size estimated and forecast for major countries
  • Company financial performance
  • Competitive landscape: Company market share analysis

Please contact us for offers on individual or multiple report purchases.

  1. Introduction
  2. Executive Summary
    • Market Size Estimation ($million, 2021-2031)
    • Forecast Estimation ($million and CAGR%, 2024-2031)
  3. Research Methodology
  4. Market Landscape
    • Market Dynamics
      • Drivers
      • Barriers
      • Opportunities
    • Market Share Analysis
      • Companies
      • Drugs
    • Market Trends Analysis
      • Key success factors
      • Market Growth Rate
    • Market Attractiveness Analysis
    • Market Profitability Analysis
      • Buyer power
      • Supplier power
      • Barriers to entry
      • Threat of substitute products
      • Rivalry among firms in the industry
    • Distribution Channels
  5. Market Segmentation [refer Market Segments and Companies Tab]
    • Drug Class or Drug (Brand) Type
    • Drug or Disorder Test
    • Indication Type
    • Drug Treatment
    • Mechanism of Action
    • Therapeutic Area or Nature of Application
    • End User Groups
  6. Geography (Region, Country)
    • North America (U.S., Canada)
    • Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
    • Asia Pacific (Japan, China, India, Rest of APAC)
    • Latin America (Brazil, Mexico, Rest of LA)
    • Rest of the World (Middle East & Africa)
  7. Regulatory Overview 
    • IND, NDA filed, FDA, EMEA Approvals
  8. Pipeline Analysis(Phase 1, 2 and 3 Drugs)
    • Phase 3 Drugs Forecast Estimation (Approval to 2031)
    • Phase 1 and 2 Drugs – Qualitative Analysis
  9. Company Profiles [refer Market Segments and Companies Tab]
    • Company Overview
    • Financial Snapshot
    • Product Portfolio
    • Business Strategies
    • Recent Developments
  10. Recommendations
  11. References

Key Questions Answered:
1. What are the factors driving and limiting this market, key success factors and challenges?
2. Which are the leading competitors in the market, their market share, profitability and key trends by product, technology, services portfolio?
3. How do markets perform between countries and regions?
4. What market segments are contributing to maximum share and greatest growth?
5. What are the product or procedure volumes by country and regions?

Actionable Insights Included:
1. Product portfolio matrix (Share vs. Growth)
2. Market attractiveness (Region vs. Growth)
3. Spot matrix (Product vs. Region)
4. Geographic distribution matrix (Share vs. Growth)

Aneurysmal Subarachnoid Hemorrhage Drugs Market

1. Drug Class
1.1. Anticonvulsant
1.2. Calcium Channel Blocker
1.3. Opioid Analgesic,
1.4. Osmotic Agent/Diuretic
1.5. Stool Softener
1.6. Other Drugs

2. Geography (Region, Country)
2.1. North America (U.S., Canada)
2.2. Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
2.3. Asia Pacific (Japan, China, India, Rest of APAC)
2.4. Latin America (Brazil, Mexico, Rest of LA)
2.5. Rest of the World

3. Company Profiles
3.1. Arbor Pharmaceuticals Inc.
3.2. Edge Therapeutics, Inc.
3.3. Johnson & Johnson (Actelion Pharmaceuticals Ltd.)
3.4. Mylan N.V.
3.5. Orexo AB
3.6. Pfizer Inc.
3.7. Purdue Pharma L.P.
3.8. Pharmaxis, Ltd.
3.9. Sun Pharmaceutical Industries Ltd.
3.10. Teva Pharmaceutical Industries Ltd. (Cephalon, Inc.).

    Request ToC / Sample Report

    Full Name*

    Company Email*

    Phone Number* [Please add country code]

    Subject*

    Message*

    Secure Online Payment

    iHealthcareAnalyst, Inc.

    Contact Address

    US Office: 2109, Mckelvey Hill Drive, Maryland Heights, MO 63043, United States
    Phone: +1 (314) 315-4764
    India Office: 5, Shilpa Chambers, Opp. J. M. Road, Shivajinager, Pune 411005, India
    Phone: +91 (20) 25898524
    Email: sales@ihealthcareanalyst.com